ARYL SULPHATASE B (MUCOPOLYSACCHARIDOSIS- VI / MAROTEAUX-LAMY) QUANTITATIVE - BLOOD

Aryl Sulphatase B (Mucopolysaccharidosis-VI / Maroteaux-Lamy) Quantitative - Blood is a specialized enzyme assay used to measure arylsulfatase B activity in a blood specimen. Arylsulfatase B is a lysosomal enzyme responsible for breaking down specific glycosaminoglycans, particularly dermatan sulfate.

Markedly reduced arylsulfatase B activity may support a diagnosis of Mucopolysaccharidosis Type VI, also known as Maroteaux-Lamy syndrome. MPS VI is a rare inherited lysosomal storage disorder caused by disease-causing variants in the ARSB gene. Enzyme results must be interpreted with clinical findings and are generally confirmed through molecular genetic testing or other specialized investigations.

Benefits of the Test

• Quantitatively measures arylsulfatase B enzyme activity.
• Supports the evaluation of suspected Mucopolysaccharidosis Type VI.
• Helps investigate clinical features suggestive of Maroteaux-Lamy syndrome.
• Supports differentiation from other mucopolysaccharidoses.
• May be used following an abnormal glycosaminoglycan screening result.
• Provides information for further genetic evaluation.
• Supports early specialist referral and disease-management planning.
• Provides laboratory-based assessment for a rare lysosomal storage disorder.

Why Doctors Recommend This Test

Doctors may recommend this test when an individual has progressive skeletal abnormalities, short stature, joint stiffness, coarse facial features, corneal clouding, enlarged liver or spleen, recurrent respiratory problems, hearing impairment, heart-valve abnormalities, hernias, or other findings suggestive of a mucopolysaccharidosis. It may also be advised after elevated urinary glycosaminoglycans or an abnormal newborn or high-risk screening result.

Preparation Before Test

• No fasting is generally required unless specifically advised by the laboratory.
• A blood specimen is collected for quantitative enzyme analysis.
• Use the specimen type and collection tube specified by the testing laboratory.
• Inform the doctor about recent blood transfusions or stem-cell transplantation.
• Share the patient's symptoms, family history, and previous metabolic test results.
• Provide urinary glycosaminoglycan and genetic-testing reports if available.
• The specimen must be stored and transported under the laboratory's specified conditions.
• Follow all collection and handling instructions carefully because enzyme activity may be affected by an unsuitable specimen.

Normal Reporting Time

Most Aryl Sulphatase B Quantitative Blood reports at Focus Diagnostics are initiated within 2–3 hours of sample receipt for specimen verification, processing, and specialized enzyme-testing workflow preparation. Because this is a specialized lysosomal enzyme assay, final analysis, validation, quality review, and reporting may require several working days depending on testing schedules and laboratory protocols.

Who Should Take This Test?

This test may be recommended for:

• Individuals with clinical features suggestive of MPS VI.
• Children with progressive skeletal abnormalities or joint stiffness.
• Patients with corneal clouding and preserved intelligence.
• Individuals with unexplained enlargement of the liver or spleen.
• Patients with elevated urinary glycosaminoglycans.
• People with a family history of Maroteaux-Lamy syndrome.
• Individuals with an abnormal lysosomal-storage-disorder screening result.
• Patients advised to undergo testing by a geneticist or metabolic specialist.

Detailed Information

Lysosomes are structures within cells that contain enzymes responsible for breaking down complex substances. Arylsulfatase B, also called N-acetylgalactosamine-4-sulfatase, helps degrade glycosaminoglycans such as dermatan sulfate.

Mucopolysaccharidosis Type VI develops when pathogenic variants in the ARSB gene result in deficient arylsulfatase B activity. The condition follows an autosomal-recessive inheritance pattern, meaning an affected individual generally inherits one altered gene copy from each parent.

When arylsulfatase B activity is deficient, partially degraded glycosaminoglycans accumulate inside lysosomes. Progressive accumulation can affect bones, joints, eyes, airways, heart valves, liver, spleen, skin, and other tissues.

Clinical severity varies considerably. Some affected individuals develop symptoms during early childhood and experience rapid disease progression, while others have a more slowly progressive form that becomes apparent later.

Common findings may include growth restriction, abnormal curvature of the spine, chest deformity, joint stiffness, reduced mobility, coarse facial features, corneal clouding, recurrent ear or respiratory infections, hearing loss, enlarged liver and spleen, hernias, sleep-related breathing problems, and cardiac-valve disease.

Intelligence is often preserved in MPS VI, although physical complications may significantly affect health and quality of life. Spinal-cord compression, airway obstruction, and cardiovascular complications require careful specialist monitoring.

Very low arylsulfatase B activity supports MPS VI but should not be interpreted alone. Improper specimen handling, reduced cell viability, recent transfusion, or other technical and biological factors may affect enzyme activity.

Additional investigations may include urinary glycosaminoglycan measurement, glycosaminoglycan fractionation, another lysosomal enzyme assay to confirm specimen integrity, ARSB gene analysis, eye examination, cardiac evaluation, hearing tests, respiratory assessment, and skeletal imaging.

Molecular genetic testing is generally used to confirm the diagnosis, identify causative ARSB variants, support family testing, and provide appropriate genetic counselling. Carrier detection usually requires genetic testing because enzyme activity may overlap between carriers and unaffected individuals.

Early diagnosis is important because condition-specific management, including enzyme-replacement therapy in appropriate patients, supportive treatment, and multidisciplinary monitoring, may reduce complications and support long-term care.

At Focus Diagnostics, Aryl Sulphatase B quantitative testing is performed using validated enzyme-assay methodologies, controlled specimen-processing procedures, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful results.